|
1.
|
|
18 p, 851.1 KB |
Clinical outcome measures in dementia with Lewy bodies trials : critique and recommendations
/
Rodriguez-Porcel, Federico (Medical University of South Carolina) ;
Wyman-Chick, Kathryn A. (HealthPartners) ;
Abdelnour, Carla (Universitat Autònoma de Barcelona) ;
Toledo, Jon B. (University of Florida) ;
Ferreira, Daniel (Mayo Clinic) ;
Urwyler, Prabitha (University of Bern) ;
Weil, Rimona S. (University College London) ;
Kane, Joseph (Queen's University) ;
Pilotto, Andrea (University of Brescia) ;
Rongve, Arvid (The University of Bergen) ;
Boeve, Bradley (Mayo Clinic) ;
Taylor, John-Paul (Newcastle University) ;
McKeith, Ian (Newcastle University) ;
Aarsland, Dag (King's College London) ;
Lewis, Simon J. G. (University of Sydney)
The selection of appropriate outcome measures is fundamental to the design of any successful clinical trial. Although dementia with Lewy bodies (DLB) is one of the most common neurodegenerative conditions, assessment of therapeutic benefit in clinical trials often relies on tools developed for other conditions, such as Alzheimer's or Parkinson's disease. [...]
2022 -  10.1186/s40035-022-00299-w
Translational Neurodegeneration, Vol. 11 (may 2022)
|
|
|
2.
|
|
1 p, 574.4 KB |
Correction : Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations
/
Rodriguez-Porcel, Federico (Medical University of South Carolina) ;
Wyman-Chick, Kathryn A. (HealthPartners) ;
Abdelnour, Carla (Universitat Autònoma de Barcelona) ;
Toledo, Jon B. (University of Florida) ;
Ferreira, Daniel (Mayo Clinic) ;
Urwyler, Prabitha (University of Bern) ;
Weil, Rimona S. (University College London) ;
Kane, Joseph (Queen's University) ;
Pilotto, Andrea (University of Brescia) ;
Rongve, Arvid (The University of Bergen) ;
Boeve, Bradley (Mayo Clinic) ;
Taylor, John-Paul (Newcastle University) ;
McKeith, Ian (Newcastle University) ;
Aarsland, Dag (King's College London) ;
Lewis, Simon J. G. (University of Sydney)
The selection of appropriate outcome measures is fundamental to the design of any successful clinical trial. Although dementia with Lewy bodies (DLB) is one of the most common neurodegenerative conditions, assessment of therapeutic benefit in clinical trials often relies on tools developed for other conditions, such as Alzheimer's or Parkinson's disease. [...]
2022 - 10.1186/s40035-022-00306-0
Translational Neurodegeneration, Vol. 11 (may 2022)
|
|
|
3.
|
|
7 p, 823.4 KB |
Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease
/
Jost, Stefanie Theresa (University of Cologne. Faculty of Medicine and University Hospital Cologne. Department of Neurology) ;
Visser-Vandewalle, Veerle (University of Cologne. Faculty of Medicine and University Hospital Cologne. Department of Stereotaxy and Functional Neurosurgery) ;
Rizos, Alexandra Marianne (King's College London. Parkinson Foundation International Centre of Excellence) ;
Loehrer, Philipp Alexander (Department of Neurology. University Hospital Giessen and Marburg. Campus Marburg) ;
Silverdale, Monty (Department of Neurology and Neurosurgery. Salford Royal NHS Foundation Trust. Manchester Academic Health Science Centre. University of Manchester) ;
Evans, Julian (Department of Neurology and Neurosurgery. Salford Royal NHS Foundation Trust. Manchester Academic Health Science Centre. University of Manchester) ;
Samuel, Michael (King's College London. Parkinson Foundation International Centre of Excellence) ;
Petry-Schmelzer, Jan Niklas (University of Cologne. Faculty of Medicine and University Hospital Cologne. Department of Neurology) ;
Sauerbier, Anna (Institute of Psychiatry. Psychology and Neuroscience. King's College London) ;
Gronostay, Alexandra (University of Cologne. Faculty of Medicine and University Hospital Cologne. Department of Neurology) ;
Barbe, Michael T. (University of Cologne. Faculty of Medicine and University Hospital Cologne. Department of Neurology) ;
Fink, Gereon R. (Cognitive Neuroscience. Institute of Neuroscience and Medicine (INM-3). Research Centre Jülich) ;
Ashkan, Keyoumars (King's College London. Parkinson Foundation International Centre of Excellence) ;
Antonini, Angelo (Padova University. Department of Neurosciences (DNS)) ;
Martinez-Martin, Pablo (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Chaudhuri, Kallol Ray (King's College London. Institute of Psychiatry, Psychology & Neuroscience) ;
Timmermann, Lars (University Hospital Giessen and Marburg) ;
Dafsari, Haidar S. (University of Cologne. Faculty of Medicine and University Hospital Cologne. Department of Neurology) ;
Bhidayasiri, Roongroj (Chulalongkorn Centre of Excellence for Parkinson's Disease & Related Disorders. Department of Medicine. Faculty of Medicine. Chulalongkorn University and King Chulalongkorn Memorial Hospital. Thai Red Cross Society) ;
Falup-Pecurariu, Cristian (Faculty of Medicine. Transilvania University of Brașov) ;
Jeon, Beomseok (Department of Neurology. Seoul National University College of Medicine) ;
Leta, Valentina (King's College London. Institute of Psychiatry. Psychology & Neuroscience) ;
Borghammer, Per (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Odin, Per (University of Lund. Faculty of Medicine) ;
Schrag, Anette (UCL Institute of Neurology (Regne Unit)) ;
Storch, Alexander (German Center for Neurodegenerative Diseases (DZNE). Research Site Dresden) ;
Rodríguez-Violante, Mayela (Movement Disorders Clinic. National Institute of Neurology and Neurosurgery) ;
Weintraub, Daniel (Parkinson's Disease and Mental Illness Research. Education and Clinical Centers. Philadelphia Veterans Affairs Medical Center) ;
Adler, Charles (The Parkinson's Disease and Movement Disorders Center. Department of Neurology. Mayo Clinic) ;
Barone, Paolo (Center for Neurodegenerative Diseases (CEMAND). Neuroscience Section. University of Salerno) ;
Brooks, David J. (Department of Nuclear Medicine and PET Centre. Aarhus University Hospital) ;
Brown, Richard (Department of Medicine. University of Birmingham Institute of Cardiovascular Sciences. City Hospital) ;
Cantillon, Marc (Reviva Pharmaceuticals. Inc) ;
Carroll, Camille (Faculty of Medicine and Dentistry. University of Plymouth) ;
Coelho, Miguel (FAS Center for Systems Biology. Harvard University) ;
Henriksen, Tove (Movement Disorder Clinic. University Hospital of Bispebjerg) ;
Hu, Michele (Nuffield Department of Clinical Neurosciences. University of Oxford) ;
Jenner, Peter (Neurodegenerative Diseases Research Group. Institute of Pharmaceutical Sciences. Faculty of Life Sciences and Medicine. King's College London) ;
Kramberger, Milica (Department of Neurology. University Medical Centre Ljubljana) ;
Kumar, Padma (Parkinson's Disease Service for the Older Person. Rankin Park Centre. John Hunter Hospital. HNELHD) ;
Kurtis, Monica M. (Functional Movement Disorders Unit. Movement Disorders Program. Neurology Department. Hospital Ruber Internacional) ;
Lewis, Simon (Brain and Mind Centre. University of Sydney) ;
Litvan, Irene (Department of Neurosciences Movement Disorders Center. University of California) ;
Lyons, Kelly (University of Kansas Medical Center) ;
Martino, Davide (Department of Clinical Neurosciences. University of Calgary & Hotchkiss Brain Institute) ;
Masellis, Mario (Hurvitz Brain Sciences Program. Sunnybrook Research Institute) ;
Mochizuki, Hideki (Department of Neurology. Osaka University Graduate School of Medicine) ;
Morley, James F. (Department of Neurology. University of Pennsylvania) ;
Nirenberg, Melissa (Department of Neurology. NYU School of Medicine) ;
Pagonabarraga Mora, Javier (Institut d'Investigació Biomèdica Sant Pau) ;
Panicker, Jalesh (Neurology. National Hospital for Neurology & Neurosurgery) ;
Pavese, Nicola (Newcastle Magnetic Resonance Centre & Positron Emission Tomography Centre. Newcastle University. Campus for Ageing & Vitality) ;
Pekkonen, Eero (Department of Neurology. Helsinki University Hospital. and Department of Neurological Sciences (Neurology). University of Helsinki) ;
Postuma, Ron (Research Institute of McGill University Health Centre) ;
Rosales, Raimon L. (Center for Neurodiagnostic and Therapeutic Services. Metropolitan Medical Center) ;
Schapira, Anthony (Department of Clinical Neurosciences. University College London (UCL) Institute of Neurology. Royal Free Campus. Rowland Hill Street) ;
Simuni, Tanya (Department of Neurology. Northwestern University. Feinberg School of Medicine) ;
Stocchi, Fabrizio (University and Institute for Research and Medical Care. IRCCS San Raffaele) ;
Subramanian, Indu (UCLA/West LA VA) ;
Tagliati, Michele (Cedars-Sinai Medical Center) ;
Tinazzi, Michele (Department of Neuroscience. Biomedicine. and Movement. University of Verona) ;
Toledo, Jon (Department of Neurology. Houston Methodist Hospital) ;
Tsuboi, Yoshio (Department of Neurology. Fukuoka University) ;
Walker, Richard (Northumbria Healthcare NHS Foundation Trust. North Tyneside General Hospital. Rake Lane)
To identify predictors of 36-month follow-up quality of life (QoL) outcome after bilateral subthalamic nucleus deep brain stimulation (STN-DBS) in Parkinson's disease (PD). In this ongoing, prospective, multicenter international study (Cologne, Manchester, London) including 73 patients undergoing STN-DBS, we assessed the following scales preoperatively and at 6-month and 36-month follow-up: PD Questionnaire-8 (PDQ-8), NMSScale (NMSS), Scales for Outcomes in PD (SCOPA)-motor examination, -activities of daily living, and -complications, and levodopa equivalent daily dose (LEDD). [...]
2021 - 10.1038/s41531-021-00174-x
NPJ Parkinson's disease, Vol. 7 Núm. 1 (december 2021) , p. 48
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
